SCHEMBL30228258

SCHEMBL30228258

COC(=O)[C@@H](C)Oc1ccc2c(-c3c(C)cccc3C)cc(=O)oc2c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH2 P05091 1/20 0.73
▸ ALDH1A1 P00352 11/20 0.64
▸ HPGD P15428 10/20 0.64
▸ AR P10275 1/20 0.56
▸ KDM4E B2RXH2 8/20 0.55
▸ RECQL P46063 2/20 0.55
▸ HSD17B10 Q99714 3/20 0.54
▸ HTT P42858 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ RAB9A P51151 1/20 0.50
▸ KLK7 P49862 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ IGLV6-57 P01721 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228157 0.89 ALDH2 (0.73) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL30228225 0.89 ALDH1A1 (0.73) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL21629539 0.84 ALDH1A1 (0.80) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL21677082 0.82 ALDH1A1 (0.72) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL30762949 0.80 ALDH1A1 (0.65) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL20839119 0.80 ALDH1A1 (0.65) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL20839174 0.79 ALDH1A1 (0.59) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL20839176 0.79 ALDH1A1 (0.59) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL20839098 0.79 ALDH1A1 (0.64) ALDH2ALDH1A1HPGDARKDM4E
SCHEMBL30228044 0.79 ALDH1A1 (0.60) ALDH2ALDH1A1HPGDARKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
US-20240368106-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2024-11-07 — — US disclosed
WO-2023034340-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed
WO-2023034339-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM ALDH2 461/4885ALDH1A1 3178/4885HPGD 2486/4885
US-20240368106-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT POLRMT, ACAT1, TFAM ALDH2 62/4885ALDH1A1 909/4885HPGD 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback